Patents Assigned to MedImmune, LLC
  • Patent number: 9598687
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 21, 2017
    Assignee: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese
  • Patent number: 9580509
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Patent number: 9580461
    Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
  • Publication number: 20170051066
    Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 23, 2017
    Applicant: MedImmune, LLC
    Inventors: Roberto DEPAZ, Natalie DEJESUS, Jared BEE
  • Patent number: 9574000
    Abstract: Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immunospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 21, 2017
    Assignees: MedImmune, LLC, The Johns Hopkins University
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen, Michael Glen Overstreet
  • Patent number: 9567389
    Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 14, 2017
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Herren Wu
  • Patent number: 9562100
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 7, 2017
    Assignees: MedImmune LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Patent number: 9527905
    Abstract: Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Lei Hua, Partha Chowdhury, Reena Varkey, Melissa Damschroder, Li Peng, Vaheh Oganesyan, Jamese Johnson Hilliard
  • Patent number: 9527927
    Abstract: The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Partha S. Chowdhury, Vaheh Oganesyan, Yariv Mazor, Nazzareno Dimasi
  • Publication number: 20160339114
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Application
    Filed: August 8, 2016
    Publication date: November 24, 2016
    Applicant: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 9499590
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: November 22, 2016
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, JoAnn Suzich
  • Patent number: 9493570
    Abstract: The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: November 15, 2016
    Assignee: MedImmune, LLC
    Inventors: Brandon Higgs, Yihong Yao, Bing Wang, Lorin Roskos, Linda Chang
  • Publication number: 20160257733
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus-associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: November 5, 2013
    Publication date: September 8, 2016
    Applicant: MEDIMMUNE, LLC
    Inventors: Brett SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
  • Publication number: 20160251441
    Abstract: Described herein is a method for separating antibody fragment impurities from target antibodies or desired fragments thereof.
    Type: Application
    Filed: October 23, 2014
    Publication date: September 1, 2016
    Applicant: MedImmune, LLC
    Inventors: Ellen T. O'CONNOR, Mutsa Y. KAMBARAMI, Matthew T. ASPELUND, Frank L. BARTNIK, Mark BERGE, Thoa BUI, Methal ALBARGHOUTHI, Jihong WANG, Jun KIM
  • Patent number: 9427479
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 30, 2016
    Assignee: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Publication number: 20160237162
    Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: September 23, 2014
    Publication date: August 18, 2016
    Applicant: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
  • Patent number: 9403901
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 2, 2016
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Publication number: 20160159913
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2015
    Publication date: June 9, 2016
    Applicant: MEDIMMUNE LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20160159886
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 9, 2016
    Applicant: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Patent number: 9308257
    Abstract: The present invention provides stable lyophilized formulations of bispecific antibodies or fragments thereof.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: April 12, 2016
    Assignee: MedImmune, LLC
    Inventors: Monika S. Sharma, Sr., Ambarish Shah, Scott Hammond